%0 Journal Article
%T ¦Ø-Conotoxins GVIA, MVIIA and CVID: SAR and Clinical Potential
%A Christina I. Schroeder
%A Richard J. Lewis
%J Marine Drugs
%D 2006
%I MDPI AG
%R 10.3390/md403193
%X Highly selective N-type voltage-gated calcium (CaV) channel inhibitors from cone snail venom (the ¦Ø-conotoxins) have emerged as a new class of therapeutics for the treatment of chronic and neuropathic pain. Earlier in 2005, Prialt (Elan) or synthetic ¦Ø-conotoxin MVIIA, was the first ¦Ø-conotoxin to be approved by Food and Drug Administration for human use. This review compares the action of three ¦Ø-conotoxins, GVIA, MVIIA and CVID, describing their structure-activity relationships and potential as leads for the design of improved N-type therapeutics that are more useful in the treatment of chronic pain.
%K ¦Ø-conotoxin
%K Structure-Activity relationship
%K pain
%U http://www.mdpi.com/1660-3397/4/3/193